Tools
Stock profile

Oruka Therapeutics, Inc. (ORKA)

ORKA · Latest close $95.74 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$95.74
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
1 / 1
vs previous quarter
Trimmed / exited
4
vs previous quarter

Oruka Therapeutics, Inc. (ORKA) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 1 fund adding, and 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $20.6M sold). Latest close $95.74 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-20.6M
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Paradigm Biocapital Advisors · Deep Track Capital · RTW Investments — 6 tracked funds hold ORKA. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 63 sales ($20.6M). Insider trading

Often held alongside

Altimmune, Inc. (ALT) · CENTURY THERAPEUTICS INC (IPSC) · KARDIGAN INC (KARD) · SOLID BIOSCIENCES INC (SLDB) · CORVUS PHARMACEUTICALS INC (CRVS) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Paradigm Biocapital Advisors3.82%2,144,526TRIMMED (-7.6%) Q3 filed Nov 16
Deep Track Capital2.67%1,926,000TRIMMED (-5.3%) Q3 filed Nov 16
RTW Investments2.55%3,139,030ADDED (+52.5%) Q3 filed Nov 16
Perceptive Advisors1.92%1,345,063TRIMMED (-3.6%) Q3 filed Nov 16
RA Capital Management1.29%1,554,597NEW Q3 filed Nov 16
Viking Global Investors0.41%1,503,478TRIMMED (-43.6%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +3.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

113.082.532024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding258 of 8,857 filers
Long-only filers among them257
Change vs 2026 Q1+80 net · 251 entered · 171 exited
Shares reported, all filers74,134,303
Reported value, all filers$6.8B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Net income · FY2025$-105.4M
Total assets · FY2025$488.6M
Shares outstanding66,209,699
Market cap (at latest close)$6.3B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20266,112,214
Share of shares outstanding9.23%
Days to cover7.26

Shares short at recent settlements — Jul 31, 2026: 8.1M · Aug 14, 2026: 8.3M · Aug 31, 2026: 7.8M · Sep 15, 2026: 7.6M · Sep 30, 2026: 7.8M · Oct 15, 2026: 6.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 476 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 63 sales by 6 insiders ($20.6M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell2,600$99.52$258.7KSEC filing
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell1,500$100.48$150.7KSEC filing
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell1,900$101.53$192.9KSEC filing
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell300$102.47$30.7KSEC filing
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell200$103.36$20.7KSEC filing
Nov 16, 2026Goncalves JoanaChief Medical OfficerSell500$105.86$52.9KSEC filing
Nov 12, 2026Agarwal ArjunSenior Vice President, FinanceSell500$101.98$51.0KSEC filing
Nov 12, 2026Agarwal ArjunSenior Vice President, FinanceSell801$103.16$82.6KSEC filing
Nov 12, 2026Agarwal ArjunSenior Vice President, FinanceSell799$104.25$83.3KSEC filing
Nov 12, 2026Agarwal ArjunSenior Vice President, FinanceSell6,842$105.28$720.3KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 1, 2026LAWRENCE KLEINDirector, Officer25,000$2.1MOct 1, 2026SEC filing
Sep 21, 2026Arjun AgarwalOfficer533$50.6KSep 21, 2026SEC filing
Sep 1, 2026LAURA SANDLEROfficer5,000$463.1KSep 1, 2026SEC filing
Sep 1, 2026LAWRENCE KLEINDirector, Officer75,000$6.9MSep 1, 2026SEC filing
Aug 14, 2026PAUL QUINLANOfficer71,000$7.7MAug 14, 2026SEC filing
Jul 15, 2026JOANA GONCALVESOfficer21,000$1.8MJul 15, 2026SEC filing
Jul 13, 2026Arjun AgarwalOfficer28,588$2.5MJul 13, 2026SEC filing
Jul 1, 2026Fairmount Healthcare Fund II L.P.Director, 10% Stockholder3,553,410$300.0MJul 1, 2026SEC filing
Jun 11, 2026CARL DAMBKOWSKIDirector35,000$2.2MJun 11, 2026SEC filing
May 21, 2026CARL DAMBKOWSKIDirector105,000$6.4MMay 21, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jul 1, 2026SCHEDULE 13D/A+13.0% (close Jul 2, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jul 2, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026RTW Investments, LPSC 13G3,139,0305.2%Jun 30, 2026SEC filing
Aug 14, 2026Venrock Healthcare Capital Partners III, L.P.SC 13G/A4,556,9527.4%Jun 30, 2026SEC filing
Aug 14, 2026VIKING GLOBAL INVESTORS LPSC 13G/A1,503,4782.5%Jun 30, 2026SEC filing
Aug 12, 2026Capital World InvestorsSC 13G3,401,6395.6%Jun 30, 2026SEC filing
Jul 1, 2026Fairmount Funds Management LLCSC 13D/A14,553,89519.5%Jul 1, 2026SEC filing
May 15, 2026VIKING GLOBAL INVESTORS LPSC 13G/A2,666,6905.3%Mar 31, 2026SEC filing
May 4, 2026Fairmount Funds Management LLCSC 13D/A13,665,08020.0%Apr 30, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026RTW Investments, LPSC 13G/A2,058,1484.3%Dec 31, 2025SEC filing
Feb 13, 2026Deep Track Capital, LPSC 13G/A2,161,5104.5%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold ORKA — ranked by lift, the co-holding pattern described in Methodology: Altimmune, Inc. (ALT) · CENTURY THERAPEUTICS INC (IPSC) · KARDIGAN INC (KARD) · SOLID BIOSCIENCES INC (SLDB) · CORVUS PHARMACEUTICALS INC (CRVS) · Damora Therapeutics, Inc. (DMRA) · GH Research PLC (GHRS) · Vaxcyte, Inc. (PCVX).

Recent 8-K filings

FiledItemsSource
Oct 26, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Aug 24, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Aug 10, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Altimmune, Inc. (ALT) · Track Record: how the signals scored · Practice timing on ORKA

One email a week: the week’s new filings and research. Subscribe free

← ORIC  ·  ORLY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.